Form D · Biotechnology
Nabriva Therapeutics plc
Dublin 1, L2 · CIK 0001641640
Offering snapshot reported Jul 27, 2018 · SEC filing
- Reported sold
- $21.3M Offering amount: $26.9M
- Investors reported
- 67 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 24, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 27, 2018 | Initial | $21,301,451 | No comparison | 67 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-317965
Source: Form D, filed Jul 27, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Axel Bolte | Director |
| Carrie Bourdow | Director |
| Colin Broom | Director |
| Daniel Burgess | Director |
| Mark Corrigan | Director |
| Robert Crotty | Executive |
| Steven Gelone | Executive |
| Francesco Maria Lavino | Executive |
| Charles A. Rowland | Director |
| Jennifer Schranz | Executive |
| Theodore Schroeder | Director, Executive |
| Gary Sender | Executive |
| George H. Talbot | Director |
| Stephen Webster | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
25 28 North Wall Quay Ifsc
Dublin 1, L2, 2
Dublin 1, L2, 2